Instem plc Trading Update and Notice of Interim Results (4887U)

TIDMINS

RNS Number : 4887U

Instem plc

30 July 2015

Instem plc

("Instem" or "the Company")

Trading Update and Notice of Interim Results

Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, provides its trading update for the six month period to 30 June 2015. Instem will be announcing its Interim Results on Tuesday 29 September 2015.

In line with management expectations, the encouraging market dynamics for the pre-clinical and clinical industries which helped to generate a record order book as we entered 2015, began to be converted into positive financial results in the first six months of the financial year and this performance has continued post the period end. Therefore, trading for full-year to 31 December 2015 is expected to be in line with market expectations.

Management will be hosting a presentation for analysts on the day of the results at 9.30am at the offices of Walbrook PR, 4 Lombard Street, London, EC3V 9HD. Analysts wishing to attend the presentation should register their interest by emailing instem@walbrookpr.com or by telephoning 020 7933 8780.

Phil Reason, CEO of Instem plc, commented: "The first half results of the current financial year reflect many of the investments in people and products the Company made during the previous year. We continue to see positive trends across our target markets and Management remains confident it can continue to deliver further growth over the remainder of the year."

For further information, please contact:

 
 Instem plc                         Tel: +44 (0) 1785 825 600 
 Phil Reason, CEO                              www.instem.com 
 Nigel Goldsmith, CFO 
 
 N+1 Singer (Nominated Adviser      Tel: +44 (0) 20 7496 3000 
  & Broker) 
 Richard Lindley 
 Nick Owen 
 
 Walbrook PR Ltd                 Tel: +44 (0) 20 7933 8780 or 
 Paul Cornelius                         instem@walbrookpr.com 
 Helen Cresswell 
 Sam Allen

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with an additional location in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

TSTLLFLRDVIAFIE

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024